Peng Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peng Gao has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Liqun Jiao
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
11 shared publications Xuebing Feng
Xuanwu Hospital Capital Medical University, Beijing, China
4 shared publications- Bin Yang
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
3 shared publications - Tao Wang
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
3 shared publications Xiaoxin He
Department of Interventional Neuroradiology, Beijing Neurosurgical Institute, Beijing, China
3 shared publicationsYan Ma
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University and China International Neuroscience Institute (China-INI), Beijing (J.L., T.W., R.X., H.G., X.Z., J.W., R.Y., P.G., Y.M., L.J.).
3 shared publications
Latest Publications
- 3 June 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Preprocedural acute silent ischemic lesions and inhospital stroke after percutaneous transluminal angioplasty and stenting for severe symptomatic intracranial atherosclerotic stenosis
Background and aims: Acute silent ischemic lesions (ASILs) usually present as diffusion weighted imaging hyperintensity with corresponding apparent diffusion coefficient hypointensity, indicating a possibly unstable ischemic pattern in severe intracranial stenosis. However, there is still no conclusive evidence that preprocedural ASILs are associated with inhospital stroke after percutaneous transluminal angioplasty and stenting (PTAS). Methods: A single center retrospective cohort study was conducted among patients with severe symptomatic intracranial atherosclerotic stenosis (severe sICAS) who underwent PTAS at a tertiary care center between January 2019 and October 2024. Among 1727 initially screened patients, 1427 eligible patients were included according to preprocedural ASIL status. The primary endpoint was prespecified as stroke or death during the index hospitalization. Multivariable logistic regression was used to evaluate the association between ASILs and the primary endpoint. Sensitivity analyses included propensity score matching, inverse probability of treatment weighting using winsorized stabilized weights, doubly robust weighted modeling using the same winsorized stabilized weights, Firth penalized logistic regression, early period exclusion analyses, and parsimonious models addressing events-per-variable concerns. Apparent within cohort discrimination and reclassification were assessed by the area under the receiver operating characteristic curve, DeLong test, continuous net reclassification improvement, and integrated discrimination improvement. Results: Of the 1427 participants, 60 (4.2%) had the primary endpoint, all of which were inhospital stroke events; no inhospital deaths occurred. Preprocedural ASILs were associated with inhospital stroke in univariable analysis (OR 4.62, 95% CI 2.68 to 7.98; P<0.001) and remained independently associated with inhospital stroke in the prespecified multivariable model (OR 5.00, 95% CI 2.70 to 9.26; P<0.001). The association remained consistent in propensity score matching (OR 4.20, 95% CI 1.58 to 11.14; P=0.004), inverse probability of treatment weighting using winsorized stabilized weights (OR 3.94, 95% CI 2.16 to 7.18; P<0.001), doubly robust weighted modeling using the same winsorized stabilized weights (OR 4.12, 95% CI 2.26 to 7.52; P<0.001), and Firth penalized logistic regression (OR 4.72, 95% CI 2.57 to 8.56; P<0.001). Adding ASIL status to the prespecified clinical model increased the apparent AUC from 0.705 to 0.763 (DeLong P=0.010) and improved reclassification. Conclusions: Preprocedural ASILs were independently associated with inhospital stroke after PTAS in patients with severe sICAS. Incorporation of ASIL status into a prespecified clinical model was associated with improved apparent within cohort discrimination and reclassification, but external validation is required before clinical application.
- 3 June 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Preprocedural acute silent ischemic lesions and inhospital stroke after percutaneous transluminal angioplasty and stenting for severe symptomatic intracranial atherosclerotic stenosis
Background and aims: Acute silent ischemic lesions (ASILs) usually present as diffusion weighted imaging hyperintensity with corresponding apparent diffusion coefficient hypointensity, indicating a possibly unstable ischemic pattern in severe intracranial stenosis. However, there is still no conclusive evidence that preprocedural ASILs are associated with inhospital stroke after percutaneous transluminal angioplasty and stenting (PTAS). Methods: A single center retrospective cohort study was conducted among patients with severe symptomatic intracranial atherosclerotic stenosis (severe sICAS) who underwent PTAS at a tertiary care center between January 2019 and October 2024. Among 1727 initially screened patients, 1427 eligible patients were included according to preprocedural ASIL status. The primary endpoint was prespecified as stroke or death during the index hospitalization. Multivariable logistic regression was used to evaluate the association between ASILs and the primary endpoint. Sensitivity analyses included propensity score matching, inverse probability of treatment weighting using winsorized stabilized weights, doubly robust weighted modeling using the same winsorized stabilized weights, Firth penalized logistic regression, early period exclusion analyses, and parsimonious models addressing events-per-variable concerns. Apparent within cohort discrimination and reclassification were assessed by the area under the receiver operating characteristic curve, DeLong test, continuous net reclassification improvement, and integrated discrimination improvement. Results: Of the 1427 participants, 60 (4.2%) had the primary endpoint, all of which were inhospital stroke events; no inhospital deaths occurred. Preprocedural ASILs were associated with inhospital stroke in univariable analysis (OR 4.62, 95% CI 2.68 to 7.98; P<0.001) and remained independently associated with inhospital stroke in the prespecified multivariable model (OR 5.00, 95% CI 2.70 to 9.26; P<0.001). The association remained consistent in propensity score matching (OR 4.20, 95% CI 1.58 to 11.14; P=0.004), inverse probability of treatment weighting using winsorized stabilized weights (OR 3.94, 95% CI 2.16 to 7.18; P<0.001), doubly robust weighted modeling using the same winsorized stabilized weights (OR 4.12, 95% CI 2.26 to 7.52; P<0.001), and Firth penalized logistic regression (OR 4.72, 95% CI 2.57 to 8.56; P<0.001). Adding ASIL status to the prespecified clinical model increased the apparent AUC from 0.705 to 0.763 (DeLong P=0.010) and improved reclassification. Conclusions: Preprocedural ASILs were independently associated with inhospital stroke after PTAS in patients with severe sICAS. Incorporation of ASIL status into a prespecified clinical model was associated with improved apparent within cohort discrimination and reclassification, but external validation is required before clinical application.
- 3 December 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 43
A laboratory-based frailty index predicts mortality in ischemic stroke with carotid artery stenosis: a retrospective analysis from the MIMIC-IV database
Ischemic stroke (IS), particularly due to carotid artery stenosis (CAS), is a major global contributor to mortality and disability. Frailty, characterized by systemic physiological decline and reduced homeostatic reserves, has emerged as a powerful prognostic marker across a wide range of diseases. We aimed to evaluate the prognostic utility of a laboratory-based frailty index (FI-Lab) in patients with IS secondary to CAS (IS-CAS), focusing on short- and long-term mortality. Data were extracted from the MIMIC-IV database. FI-Lab was calculated using 33 routine tests within 24 h of ICU admission. Patients were stratified into quartiles based on FI-Lab scores. Cox proportional hazards models, restricted cubic splines, Kaplan-Meier curves, and subgroup analyses were applied. Among 1,869 IS-CAS patients, higher FI-Lab scores were independently associated with increased 30-day and 1-year mortality (p for trend < 0.001). The highest quartile had a significantly elevated hazard ratio compared to the lowest. Survival curves and RCS analyses supported a linear association. Subgroup analysis showed consistent trends, especially in patients not receiving mechanical ventilation. FI-Lab is a robust predictor of both short- and long-term mortality in IS-CAS. It holds promise for individualized risk stratification and could aid clinical decision-making in stroke management.
- 3 December 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 43
A laboratory-based frailty index predicts mortality in ischemic stroke with carotid artery stenosis: a retrospective analysis from the MIMIC-IV database
Ischemic stroke (IS), particularly due to carotid artery stenosis (CAS), is a major global contributor to mortality and disability. Frailty, characterized by systemic physiological decline and reduced homeostatic reserves, has emerged as a powerful prognostic marker across a wide range of diseases. We aimed to evaluate the prognostic utility of a laboratory-based frailty index (FI-Lab) in patients with IS secondary to CAS (IS-CAS), focusing on short- and long-term mortality. Data were extracted from the MIMIC-IV database. FI-Lab was calculated using 33 routine tests within 24 h of ICU admission. Patients were stratified into quartiles based on FI-Lab scores. Cox proportional hazards models, restricted cubic splines, Kaplan-Meier curves, and subgroup analyses were applied. Among 1,869 IS-CAS patients, higher FI-Lab scores were independently associated with increased 30-day and 1-year mortality (p for trend < 0.001). The highest quartile had a significantly elevated hazard ratio compared to the lowest. Survival curves and RCS analyses supported a linear association. Subgroup analysis showed consistent trends, especially in patients not receiving mechanical ventilation. FI-Lab is a robust predictor of both short- and long-term mortality in IS-CAS. It holds promise for individualized risk stratification and could aid clinical decision-making in stroke management.
- 1 May 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (5) , 1128-1137
Stenting Versus Medical Therapy for Symptomatic Intracranial Artery Stenosis: Long-Term Follow-Up of a Randomized Trial
BACKGROUND: Whether the long-term benefit of stroke prevention when stenting is added to medical therapy (MT) over MT alone for symptomatic severe intracranial artery stenosis offsets the perioperative risks of the stenting has not been directly evaluated in a randomized trial. We aimed to compare the long-term (>3 years) effect of stenting versus MT alone in patients with symptomatic severe intracranial artery stenosis in a randomized trial. METHODS: We extended the follow-up of 358 subjects enrolled in a multicenter, open-label, randomized trial conducted at 8 centers in China. Patients with transient ischemic attack or stroke attributed to severe intracranial stenosis (70% to 99%) were recruited between March 5, 2014, and November 10, 2016. The primary outcome was a composite of stroke or death within 30 days or stroke in the territory of the qualifying artery beyond 30 days. Other secondary outcomes included stroke in the territory of the qualifying artery, as well as disabling stroke or death after enrollment. RESULTS: A total of 358 patients (stenting 176 versus MT 182) were recruited from March 5, 2014, and followed up till January 22, 2024. The median duration of follow-up was 7.4 years (interquartile range, 6.0–8.0). The primary outcome was not significantly different (stenting 14.8% versus MT 14.3%; hazard ratio, 1.02 [95% CI, 0.58–1.77]; P =0.97). No significant difference was found between groups for the secondary outcomes: stroke in the territory of qualifying artery (14.8% versus 14.3%; hazard ratio, 1.02 [95% CI, 0.58–1.77]; P =0.97), disabling stroke or death (16.5% versus 14.3%; hazard ratio, 1.12 [95% CI, 0.66–1.91]; P =0.70), and death (9.1% versus 7.1%; hazard ratio, 1.22 [95% CI, 0.58–2.58]; P =0.60). CONCLUSIONS: This study provides compelling evidence that, even over prolonged observed periods, the addition of stenting to MT does not confer additional benefits to MT alone in patients with symptomatic severe intracranial artery stenosis. These results underscore the importance of MT as the cornerstone of long-term stroke prevention in this patient population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01763320.
- 1 May 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (5) , 1128-1137
Stenting Versus Medical Therapy for Symptomatic Intracranial Artery Stenosis: Long-Term Follow-Up of a Randomized Trial
BACKGROUND: Whether the long-term benefit of stroke prevention when stenting is added to medical therapy (MT) over MT alone for symptomatic severe intracranial artery stenosis offsets the perioperative risks of the stenting has not been directly evaluated in a randomized trial. We aimed to compare the long-term (>3 years) effect of stenting versus MT alone in patients with symptomatic severe intracranial artery stenosis in a randomized trial. METHODS: We extended the follow-up of 358 subjects enrolled in a multicenter, open-label, randomized trial conducted at 8 centers in China. Patients with transient ischemic attack or stroke attributed to severe intracranial stenosis (70% to 99%) were recruited between March 5, 2014, and November 10, 2016. The primary outcome was a composite of stroke or death within 30 days or stroke in the territory of the qualifying artery beyond 30 days. Other secondary outcomes included stroke in the territory of the qualifying artery, as well as disabling stroke or death after enrollment. RESULTS: A total of 358 patients (stenting 176 versus MT 182) were recruited from March 5, 2014, and followed up till January 22, 2024. The median duration of follow-up was 7.4 years (interquartile range, 6.0–8.0). The primary outcome was not significantly different (stenting 14.8% versus MT 14.3%; hazard ratio, 1.02 [95% CI, 0.58–1.77]; P =0.97). No significant difference was found between groups for the secondary outcomes: stroke in the territory of qualifying artery (14.8% versus 14.3%; hazard ratio, 1.02 [95% CI, 0.58–1.77]; P =0.97), disabling stroke or death (16.5% versus 14.3%; hazard ratio, 1.12 [95% CI, 0.66–1.91]; P =0.70), and death (9.1% versus 7.1%; hazard ratio, 1.22 [95% CI, 0.58–2.58]; P =0.60). CONCLUSIONS: This study provides compelling evidence that, even over prolonged observed periods, the addition of stenting to MT does not confer additional benefits to MT alone in patients with symptomatic severe intracranial artery stenosis. These results underscore the importance of MT as the cornerstone of long-term stroke prevention in this patient population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01763320.
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e032651
Alterations of Hemostatic Molecular Markers During Acute Large Vessel Occlusion Stroke
Background: This study aimed to investigate regional levels of TAT (thrombin‐antithrombin complex), PIC (plasmin‐α2 plasmin inhibitor complex), t‐PAIC (tissue plasminogen activator‐plasminogen activator inhibitor complex), sTM (soluble thrombomodulin), and D‐dimer, along with their associations with clinical and procedural characteristics in patients with acute ischemic stroke undergoing endovascular thrombectomy. Methods and Results: We retrospectively analyzed 166 consecutive patients with acute ischemic stroke (62±11.54 years of age, 34.3% women) using prospectively maintained clinical databases and blood samples from local ischemic (proximal to thrombus) and systemic (femoral artery, self‐control) arterial compartments. Levels of TAT, PIC, t‐PAIC, and D‐dimer were significantly elevated, whereas sTM was significantly reduced, in local ischemic regions compared with their systemic levels. Each 1‐unit increase in ischemic TAT (adjusted odds ratio [aOR], 1.086 [95% CI, 1.03–1.145]; P =0.002; area under the curve [AUC], 0.833) and PIC (aOR, 1.337 [95% CI, 1.087–1.644]; P =0.006; AUC, 0.771) correlated significantly with higher symptomatic intracranial hemorrhage risk. Additionally, each 1‐unit increase in ischemic TAT (aOR, 1.076 [95% CI, 1.016–1.139]; P =0.013; AUC, 0.797), PIC (aOR, 1.554 [95% CI, 1.194–2.022]; P =0.001; AUC, 0.798), and sTM (aOR, 0.769 [95% CI, 0.615–0.961]; P =0.021; AUC, 0.756) was significantly associated with an increased risk of an unfavorable 90‐day outcome (modified Rankin scale of 3–6). These hemostatic molecules, individually or combined, significantly improved the predictive power of conventional risk factors, as evidenced by significant increases in net reclassification improvement and integrated discrimination improvement (all P <0.01). Conclusions: We observed a hyperactive state of the coagulation‐fibrinolysis system within the local ischemic region during hyperacute stroke. Rapid automated measurement of hemostatic molecular markers, particularly TAT, PIC, and sTM, during intra‐arterial procedures may provide additional information for stroke risk stratification and therapeutic decision‐making, and warrants further investigation.
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e032651
Open AccessAlterations of Hemostatic Molecular Markers During Acute Large Vessel Occlusion Stroke
Background: This study aimed to investigate regional levels of TAT (thrombin‐antithrombin complex), PIC (plasmin‐α2 plasmin inhibitor complex), t‐PAIC (tissue plasminogen activator‐plasminogen activator inhibitor complex), sTM (soluble thrombomodulin), and D‐dimer, along with their associations with clinical and procedural characteristics in patients with acute ischemic stroke undergoing endovascular thrombectomy. Methods and Results: We retrospectively analyzed 166 consecutive patients with acute ischemic stroke (62±11.54 years of age, 34.3% women) using prospectively maintained clinical databases and blood samples from local ischemic (proximal to thrombus) and systemic (femoral artery, self‐control) arterial compartments. Levels of TAT, PIC, t‐PAIC, and D‐dimer were significantly elevated, whereas sTM was significantly reduced, in local ischemic regions compared with their systemic levels. Each 1‐unit increase in ischemic TAT (adjusted odds ratio [aOR], 1.086 [95% CI, 1.03–1.145]; P =0.002; area under the curve [AUC], 0.833) and PIC (aOR, 1.337 [95% CI, 1.087–1.644]; P =0.006; AUC, 0.771) correlated significantly with higher symptomatic intracranial hemorrhage risk. Additionally, each 1‐unit increase in ischemic TAT (aOR, 1.076 [95% CI, 1.016–1.139]; P =0.013; AUC, 0.797), PIC (aOR, 1.554 [95% CI, 1.194–2.022]; P =0.001; AUC, 0.798), and sTM (aOR, 0.769 [95% CI, 0.615–0.961]; P =0.021; AUC, 0.756) was significantly associated with an increased risk of an unfavorable 90‐day outcome (modified Rankin scale of 3–6). These hemostatic molecules, individually or combined, significantly improved the predictive power of conventional risk factors, as evidenced by significant increases in net reclassification improvement and integrated discrimination improvement (all P <0.01). Conclusions: We observed a hyperactive state of the coagulation‐fibrinolysis system within the local ischemic region during hyperacute stroke. Rapid automated measurement of hemostatic molecular markers, particularly TAT, PIC, and sTM, during intra‐arterial procedures may provide additional information for stroke risk stratification and therapeutic decision‐making, and warrants further investigation.
- Open Access
- 17 January 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (4) , 2065-2070
Impact of immediate postrecanalization cooling on outcome in acute ischemic stroke patients with a large ischemic core: prospective cohort study
Background: Patients with large acute ischemic strokes (AIS) often have a poor prognosis despite successful recanalization due to multiple factors including reperfusion injury. The authors aim to describe our preliminary experience of endovascular cooling in patients with a large AIS after recanalization. Methods: From January 2021 to July 2022, AIS patients presenting with large infarcts (defined as ASPECTS ≤5 on noncontrast CT or ischemic core ≥50 ml on CT perfusion) who achieved successful recanalization after endovascular treatment were analyzed in a prospective registry. Patients were divided into targeted temperature management (TTM) and non-TTM group. Patients in the TTM group received systemic cooling with a targeted core temperature of 33° for at least 48 h. The primary outcome is 90-day favorable outcome [modified Rankin Scale (mRS) 0–2]. The secondary outcomes are 90-day good outcome (mRS 0–3), mortality, intracranial hemorrhage and malignant cerebral edema within 7 days or at discharge. Results: Forty-four AIS patients were recruited (15 cases in the TTM group and 29 cases in the non-TTM group). The median Alberta Stroke Program Early CT Score (ASPECTS) was 3 (2–5). The median time for hypothermia duration was 84 (71.5–147.6) h. The TTM group had a numerically higher proportion of 90-day favorable outcomes than the non-TTM group (46.7 vs. 27.6%, P=0.210), and no significant difference were found regarding secondary outcomes (all P>0.05). The TTM group had a numerically higher rates of pneumonia (66.7 vs. 58.6%, P=0.604) and deep vein thrombosis (33.3 vs. 13.8%, P=0.138). Shivering occurred in 4/15 (26.7%) of the TTM patients and in none of the non-TTM patients (P=0.009). Conclusions: Postrecanalization cooling is feasible in patients with a large ischemic core. Future randomized clinical trials are warranted to validate its efficacy.
- 17 January 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (4) , 2065-2070
Open AccessImpact of immediate postrecanalization cooling on outcome in acute ischemic stroke patients with a large ischemic core: prospective cohort study
Background: Patients with large acute ischemic strokes (AIS) often have a poor prognosis despite successful recanalization due to multiple factors including reperfusion injury. The authors aim to describe our preliminary experience of endovascular cooling in patients with a large AIS after recanalization. Methods: From January 2021 to July 2022, AIS patients presenting with large infarcts (defined as ASPECTS ≤5 on noncontrast CT or ischemic core ≥50 ml on CT perfusion) who achieved successful recanalization after endovascular treatment were analyzed in a prospective registry. Patients were divided into targeted temperature management (TTM) and non-TTM group. Patients in the TTM group received systemic cooling with a targeted core temperature of 33° for at least 48 h. The primary outcome is 90-day favorable outcome [modified Rankin Scale (mRS) 0–2]. The secondary outcomes are 90-day good outcome (mRS 0–3), mortality, intracranial hemorrhage and malignant cerebral edema within 7 days or at discharge. Results: Forty-four AIS patients were recruited (15 cases in the TTM group and 29 cases in the non-TTM group). The median Alberta Stroke Program Early CT Score (ASPECTS) was 3 (2–5). The median time for hypothermia duration was 84 (71.5–147.6) h. The TTM group had a numerically higher proportion of 90-day favorable outcomes than the non-TTM group (46.7 vs. 27.6%, P=0.210), and no significant difference were found regarding secondary outcomes (all P>0.05). The TTM group had a numerically higher rates of pneumonia (66.7 vs. 58.6%, P=0.604) and deep vein thrombosis (33.3 vs. 13.8%, P=0.138). Shivering occurred in 4/15 (26.7%) of the TTM patients and in none of the non-TTM patients (P=0.009). Conclusions: Postrecanalization cooling is feasible in patients with a large ischemic core. Future randomized clinical trials are warranted to validate its efficacy.
- Open Access
- 5 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (2) , 974-983
Impact of acute silent ischemic lesions on clinical outcomes of carotid revascularization
Background: Previous literature has established an association between acute silent ischemic lesions (ASILs) and elevated susceptibility to future adverse clinical outcomes. The present study endeavors to scrutinize the prognostic significance of preprocedural ASILs, as detected through diffusion-weighted imaging and apparent diffusion coefficient metrics, in relation to subsequent adverse events—namely, stroke, myocardial infarction, and all-cause death—following carotid revascularization in a cohort of patients with symptomatic carotid stenosis. Materials and methods: Subjects were extracted from a comprehensive retrospective dataset involving symptomatic carotid stenosis cases that underwent carotid revascularization at a tertiary healthcare institution in China, spanning January 2019 to March 2022. Of the 2663 initially screened patients (symptomatic carotid stenosis=1600; asymptomatic carotid stenosis=1063), a total of 1172 individuals with symptomatic carotid stenosis were retained for subsequent analysis. Stratification was implemented based on the presence or absence of ASILs. The primary endpoint constituted a composite measure of in-hospital stroke, myocardial infarction, or all-cause death. Both carotid endarterectomy (CEA) and carotid artery stenting (CAS) treatment modalities were individually subjected to propensity score-matched analyses. Results: Among the 584 subjects who underwent CEA, 91 ASIL-positive and 91 ASIL-negative (NASIL) cases were propensity score-matched. Notably, the ASIL cohort demonstrated a statistically significant augmentation in the risk of primary outcomes relative to the NASIL group [10.99 vs. 1.10%; absolute risk difference, 9.89% (95% CI: 3.12–16.66%); RR, 10.00 (95% CI: 1.31–76.52); P=0.01]. Similarly, within the 588 CAS-treated patients, 107 ASIL-positive and 107 NASIL cases were matched, revealing a correspondingly elevated risk of primary outcomes in the ASIL group [9.35 vs. 1.87%; absolute risk difference, 7.48% (95% CI: 1.39–13.56%); RR, 5.00 (95% CI: 1.12–22.28); P=0.02]. Conclusions: ASILs portend an elevated risk for grave adverse events postcarotid revascularization, irrespective of the specific revascularization technique employed—be it CEA or CAS. Thus, ASILs may serve as a potent biomarker for procedural risk stratification in the context of carotid revascularization.
- 5 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (2) , 974-983
Open AccessImpact of acute silent ischemic lesions on clinical outcomes of carotid revascularization
Background: Previous literature has established an association between acute silent ischemic lesions (ASILs) and elevated susceptibility to future adverse clinical outcomes. The present study endeavors to scrutinize the prognostic significance of preprocedural ASILs, as detected through diffusion-weighted imaging and apparent diffusion coefficient metrics, in relation to subsequent adverse events—namely, stroke, myocardial infarction, and all-cause death—following carotid revascularization in a cohort of patients with symptomatic carotid stenosis. Materials and methods: Subjects were extracted from a comprehensive retrospective dataset involving symptomatic carotid stenosis cases that underwent carotid revascularization at a tertiary healthcare institution in China, spanning January 2019 to March 2022. Of the 2663 initially screened patients (symptomatic carotid stenosis=1600; asymptomatic carotid stenosis=1063), a total of 1172 individuals with symptomatic carotid stenosis were retained for subsequent analysis. Stratification was implemented based on the presence or absence of ASILs. The primary endpoint constituted a composite measure of in-hospital stroke, myocardial infarction, or all-cause death. Both carotid endarterectomy (CEA) and carotid artery stenting (CAS) treatment modalities were individually subjected to propensity score-matched analyses. Results: Among the 584 subjects who underwent CEA, 91 ASIL-positive and 91 ASIL-negative (NASIL) cases were propensity score-matched. Notably, the ASIL cohort demonstrated a statistically significant augmentation in the risk of primary outcomes relative to the NASIL group [10.99 vs. 1.10%; absolute risk difference, 9.89% (95% CI: 3.12–16.66%); RR, 10.00 (95% CI: 1.31–76.52); P=0.01]. Similarly, within the 588 CAS-treated patients, 107 ASIL-positive and 107 NASIL cases were matched, revealing a correspondingly elevated risk of primary outcomes in the ASIL group [9.35 vs. 1.87%; absolute risk difference, 7.48% (95% CI: 1.39–13.56%); RR, 5.00 (95% CI: 1.12–22.28); P=0.02]. Conclusions: ASILs portend an elevated risk for grave adverse events postcarotid revascularization, irrespective of the specific revascularization technique employed—be it CEA or CAS. Thus, ASILs may serve as a potent biomarker for procedural risk stratification in the context of carotid revascularization.
- 1 August 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (8) , E395-E396
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis
- 1 August 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (8) , E395-E396
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis
- Open Access
- 4 February 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Timing and Outcomes of Intracranial Stenting in the Post-SAMMPRIS Era: A Systematic Review
Objective: To investigate the impact of timing on the safety and efficacy of stenting for ICAS, we reviewed high-volume randomized controlled trials or prospective cohort studies of stenting for intracranial atherosclerotic artery stenosis (ICAS) after the SAMMPRIS trial.Methods: We included randomized controlled trials or prospective cohort studies since 2011 (the publication of the SAMMPRIS trial), evaluating the outcomes of intracranial stenting for ICAS patients. The primary outcomes were perioperative and 1-year stroke or death rate. The interaction of timing and outcomes were shown on trend plots. Overall meta-analysis and subgroup analysis by timing of intracranial stenting were conducted.Results: Fourteen studies with a total of 1,950 patients were included. The perioperative and post-operative stroke or death rates decreased with the time of stenting to the qualifying events. The perioperative stroke rate was significantly higher in patients treated within 21 days after the qualifying events, compared to those beyond 21 days (IRR = 1.60, 95%CI: 1.10–2.33; p = 0.014), similar relationships were obtained for both post-procedural (IRR = 1.61, 95%CI: 1.02–2.55; p = 0.042) and 1-year (IRR = 1.51, 95%CI: 1.10–2.08; p = 0.012) stroke or death rate.Conclusions: The timing of intracranial stenting may influence the safety and efficacy outcomes of stenting. Intracranial stenting within 21 days from the qualifying events may confer a higher risk of stroke or death. More studies are needed to confirm the impact of timing and the proper cut-off value.
- 4 February 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessTiming and Outcomes of Intracranial Stenting in the Post-SAMMPRIS Era: A Systematic Review
Objective: To investigate the impact of timing on the safety and efficacy of stenting for ICAS, we reviewed high-volume randomized controlled trials or prospective cohort studies of stenting for intracranial atherosclerotic artery stenosis (ICAS) after the SAMMPRIS trial.Methods: We included randomized controlled trials or prospective cohort studies since 2011 (the publication of the SAMMPRIS trial), evaluating the outcomes of intracranial stenting for ICAS patients. The primary outcomes were perioperative and 1-year stroke or death rate. The interaction of timing and outcomes were shown on trend plots. Overall meta-analysis and subgroup analysis by timing of intracranial stenting were conducted.Results: Fourteen studies with a total of 1,950 patients were included. The perioperative and post-operative stroke or death rates decreased with the time of stenting to the qualifying events. The perioperative stroke rate was significantly higher in patients treated within 21 days after the qualifying events, compared to those beyond 21 days (IRR = 1.60, 95%CI: 1.10–2.33; p = 0.014), similar relationships were obtained for both post-procedural (IRR = 1.61, 95%CI: 1.02–2.55; p = 0.042) and 1-year (IRR = 1.51, 95%CI: 1.10–2.08; p = 0.012) stroke or death rate.Conclusions: The timing of intracranial stenting may influence the safety and efficacy outcomes of stenting. Intracranial stenting within 21 days from the qualifying events may confer a higher risk of stroke or death. More studies are needed to confirm the impact of timing and the proper cut-off value.
- 1 February 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (2) , E53-E54
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis
- 1 February 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (2) , E53-E54
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis